Novo Nordisk launches Wegovy in the UK
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited launch. The drug is intended to provide new treatment options to patients living with obesity.
The drug will now be available via specialist NHS weight management services for patients meeting the National Institute for Health and Care Excellence’s (NICE) criteria or privately via a registered healthcare professional. The NHS services will also provide patients with support around diet and exercise.
Novo Nordisk has stated that it is likely that supply of the drug will be constrained for the foreseeable future, with a proportion of this supply set aside for use within the NHS to allow healthcare professionals to implement NICE guidance. The company plans to work with healthcare professionals to ensure that patients with the greatest unmet medical need are prioritised in receiving this treatment.
According to the company’s press release: “We believe the launch of Wegovy will help provide an additional option to support people living with obesity in the UK and look forward to working with healthcare providers to achieve this.”
Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent …
Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset …